All In Biotech

Drug Trial Radar · NCT06140836

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Dec 21, 2023

Primary completion

Feb 16, 2027

Study completion Mar 15, 2027

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Zai Lab (Shanghai) Co., Ltd.
First posted
Nov 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • RepotrectinibDrug

    Specified dose on specified days

  • CrizotinibDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) as per Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to approximately 41 months

Locations

120 sites in 21 countries. Site status is shown where the registry gives one.

  • Local Institution - 0075

    Boston, Massachusetts

  • Local Institution - 0201

    Boston, Massachusetts

  • Local Institution - 0210

    Mineola, New York

  • Local Institution - 0134

    New York, New York

  • Local Institution - 0106

    Buenos Aires, Argentina

  • Local Institution - 0207

    Buenos Aires, Argentina

  • Local Institution - 0093

    Córdoba, Argentina

  • Local Institution - 0092

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto Alexander Fleming

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Local Institution - 0091

    ABB, Buenos Aires F.D., Argentina

  • Local Institution - 0041

    Vienna, Austria

  • Local Institution - 0098

    Rio de Janeiro, Brazil

  • Local Institution - 0108

    Rio de Janeiro, Brazil

  • Local Institution - 0032

    São Paulo, Brazil

  • Local Institution - 0114

    São Paulo, Brazil

  • Local Institution - 0073

    Belo Horizonte, Minas Gerais, Brazil

  • Local Institution - 0033

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution - 0034

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution - 0029

    Barretos, São Paulo, Brazil

  • Local Institution - 0037

    São José do Rio Preto, São Paulo, Brazil

  • Local Institution - 0209

    São Paulo, São Paulo, Brazil

  • Local Institution - 0147

    São Paulo, São Paulo, Brazil

  • Local Institution - 0002

    Toronto, Ontario, Canada

  • Local Institution - 0123

    Trois-Rivières, Quebec, Canada

  • Fundacion Arturo Lopez Perez (FALP)

    Santiago, Santiago Metropolitan, Chile

  • Local Institution - 0096

    Viña del Mar, Valparaiso, Chile

  • Local Institution - 0168

    Beijing, Beijing Municipality, China

  • Local Institution - 0185

    Chongqing, Chongqing Municipality, China

  • Local Institution - 0169

    Xiamen, Fujian, China

  • Local Institution - 0180

    Guangzhou, Guangdong, China

  • Local Institution - 0194

    Nanning, Guangxi, China

  • Local Institution - 0171

    Harbin, Heilongjiang, China

  • Local Institution - 0166

    Zhengzhou, Henan, China

  • Local Institution - 0181

    Wuhan, Hubei, China

  • Local Institution - 0184

    Changsha, Hunan, China

  • Local Institution - 0193

    Nanjing, Jiangsu, China

  • Local Institution - 0202

    Nanchang, Jiangxi, China

  • Local Institution - 0178

    Changchun, Jilin, China

  • Local Institution - 0183

    Xi'an, Shaanxi, China

  • Local Institution - 0186

    Jinan, Shandong, China

Showing 40 of 120 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.